



## Decision Dx·MELANOMA

### **Provides precise and personalized tumor information for stage I-III cutaneous melanoma patients**

- Established prognostic test predicts individual risk of recurrence or metastasis
- Improves prognostic precision by integrating a patient's class score with clinicopathologic factors to further support two key clinical management decisions:
  - › Likelihood of sentinel lymph node biopsy positivity (i31-SLNB) for patient selection
  - › Personalized risk of recurrence (i31-ROR) for intensity of follow up, surveillance imaging and referrals



### **Improves diagnostic resolution in melanocytic lesions of uncertain malignant potential**

- Highly accurate and objective tests to aid in the classification of difficult-to-diagnose melanocytic lesions
- A comprehensive workflow that leverages the strengths of two gene expression profile (GEP) tests
- Adds diagnostic clarity and confidence for dermatopathologists while helping dermatologists deliver more informed patient management plans

## Decision Dx·SCC

### **Accurately identifies risk of metastasis in high-risk squamous cell carcinoma (SCC) patients with one or more risk factors**

- Clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors
- Provides unique, complementary information for SCC management to better inform choices about treatment and follow-up care

# DecisionDx-UM

## Evaluates metastatic risk profiles in newly diagnosed uveal melanoma patients

- The standard of care in uveal melanoma prognosis
  - › Unparalleled accuracy supported by extensive clinical evidence
  - › The only prognostic test for uveal melanoma to be validated in prospective, multicenter studies
- Demonstrated to help physicians optimize patient management based on metastatic risk
  - › National Comprehensive Cancer Network Guidelines recommend risk-appropriate metastatic screening regimens based on DecisionDx-UM test results

# tissuecypher

## BARRETT'S ESOPHAGUS ASSAY

## Independently predicts future development of esophageal cancer in patients with Barrett's esophagus

- First and only precision medicine test that:
  - › Identifies patients who are at low risk of developing high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), enabling the extension of surveillance intervals and/or reduction in unnecessary therapeutic interventions
  - › Identifies patients who are at high risk of developing HGD or EAC, enabling early therapeutic intervention to prevent EAC, or increased surveillance for early detection of EAC at a treatable stage

### Order a Test

- Test order forms, online ordering, patient reports for all Castle tests are available at [Portal.CastleBiosciences.com](https://Portal.CastleBiosciences.com)
- For ordering information or questions call:  
**866-788-9007 for DecisionDx**  
**412-820-3050 for TissueCypher**

**CASTLE**  
BIOSCIENCES  
[CastleTestInfo.com](https://CastleTestInfo.com)

